HeartLung Technologies Selected as a Finalist for ACC 2025 Innovation Pitch Challenge

Houston, TX, United States, March 17, 2025. EINPresswire.com. View Press Release.

HeartLung Technologies will compete at the ACC 2025 Innovation Pitch Challenge in Chicago on Sunday, March 30, from 3:00 – 4:15 PM CT in Booth # 17007

We are excited to announce our participation as a finalist in the 2025 American College of Cardiology (ACC) Early-Stage Innovation Pitch Challenge. The event, held during the ACC's Annual Scientific Session in Chicago, will feature HeartLung Technologies debuting our innovative AutoChamber™ AI solution for the first time.

The ACC Early-Stage Innovation Pitch Challenge is a highlight of the ACC's commitment to fostering innovation in cardiovascular care. This competition brings together the most promising early-stage companies to present their cutting-edge solutions to a panel of expert judges and an audience of healthcare professionals. The panel and audience will vote to determine the most innovative solution after the presentations.

HeartLung’s AutoChamber™ is the first FDA-approved AI to receive “Breakthrough” designation, empowering physicians to detect patients with enlarged cardiac chambers and left ventricular hypertrophy that are not visible to the human eye

In the US alone, nearly 20 million chest CT scans are performed each year, yet many asymptomatic patients with enlarged heart chambers go undetected, leading to late-stage heart failure, atrial fibrillation, stroke, and sudden cardiac death. AutoChamber™ AI addresses this gap, potentially saving numerous lives from preventable cardiovascular deaths. HeartLung is also awaiting approval for AI-CVD, which includes multiple AI modules such as AutoCAC (Automated Coronary Calcium Scoring) aimed at opportunistic screening in chest CT scans.

The ACC’s mission is to transform cardiovascular care and improve heart health. The Future Hub Theater at ACC 2025 will highlight how innovative technologies can improve patient outcomes and care. HeartLung Technologies aligns with this mission by utilizing AI to detect hidden heart conditions early, ultimately saving lives. HeartLung has already made significant strides in this area with its AI-CVD modules, including AutoCAC for automated coronary calcium scoring, which further aligns with ACC's goals.

“We are honored to be recognized by the ACC for our innovative work with AutoChamber™ AI and to be recognized as a finalist in the ACC Early-Stage Innovation Pitch Challenge. AutoChamber™ AI represents a significant advancement in cardiovascular care, and we look forward to showcasing its life-saving potential.” - Dr. Morteza Naghavi, MD, Founder and President of HeartLung Technologies.

About HeartLung Technologies

HeartLung leverages AI technology for the early detection of heart disease, lung cancer, emphysema/COPD, osteoporosis, myosteatosis, fatty liver disease, and other life-threatening conditions. HeartLung has received FDA "Breakthrough Designation" for AutoChamber™, an AI tool that identifies enlarged cardiac chambers and left ventricular hypertrophy in non-contrast chest CT scans, which are typically undetectable by the human eye. The AutoChamber™ AI also works on low-dose CT for lung cancer screening as well as contrast-enhanced coronary CT angiography (CCTA) scans. Additionally, HeartLung has obtained FDA 510(k) clearance for AutoBMD™, the only DEXA-equivalent, CT-based opportunistic osteoporosis screening approved by the FDA, applicable to over 25 million CT scans annually and reimbursed by Medicare. HeartLung is also awaiting FDA approval for AI-CVD™, a suite of AI modules including AI-CAC™ (AI-enabled Coronary Artery Calcium Scoring), aimed at early detection and prevention of cardiovascular disease using widely available CT scans.

Closing Remarks

We invite you to attend ACC 2025, see our presentation, and cast your vote! Join us in our mission to revolutionize cardiovascular care.

Explore our exciting plans for 2025.

Click here to read the official press release.